Literature DB >> 23251203

Effects of antidepressant treatment on sexual arousal in depressed women: a preliminary FMRI study.

Jong-Chul Yang1, Jong-Il Park, Gwang-Won Kim, Sung-Jong Eun, Moo-Suk Lee, Kyung-Lae Han, Jeong-Ho Chae, Gwang-Woo Jeong.   

Abstract

OBJECTIVE: There was a recent study to explore the cerebral regions associated with sexual arousal in depressed women using functional magnetic resonance imaging (fMRI). The purpose of this neuroimaging study was to investigate the effects of antidepressant treatment on sexual arousal in depressed women.
METHODS: SEVEN DEPRESSED WOMEN WITH SEXUAL AROUSAL DYSFUNCTION (MEAN AGE: 41.7±13.8, mean scores of the Beck Depression Inventory (BDI) and the 17-item Hamilton Rating Scale for Depression (HAMD-17): 35.6±7.1 and 34.9±3.1, respectively) and nine healthy women (mean age: 40.3±11.6) underwent fMRI before and after antidepressant treatment. The fMRI paradigm contrasted a 1 minute rest period viewing non-erotic film with 4 minutes of sexual stimulation viewing an erotic video film. Data were analyzed by SPM 2. The relative number of pixels activated in each period was used as an index of activation. All depressed women were treated with mirtazapine (mean dosage: 37.5 mg/day) for 8 to 10 weeks.
RESULTS: Levels of brain activity during sexual arousal in depressed women significantly increased with antidepressant treatment (p<0.05) in the regions of the hypothalamus (3.0% to 11.2%), septal area (8.6% to 27.8%) and parahippocampal gyrus (5.8% to 14.6%). Self-reported sexual arousal during visual sexual stimulation also significantly increased post-treatment, and severity of depressive symptoms improved, as measured by the BDI and HAMD-17 (p<0.05).
CONCLUSION: These results show that sexual arousal dysfunction of depressed women may improve after treatment of depression, and that this improvement is associated with increased activation of the hypothalamus, septal area, and parahippocampal gyrus during sexual arousal.

Entities:  

Keywords:  Cerebral region; Depression; Functional magnetic resonance imaging (fMRI); Sexual arousal; Treatment; Women

Year:  2012        PMID: 23251203      PMCID: PMC3521115          DOI: 10.4306/pi.2012.9.4.379

Source DB:  PubMed          Journal:  Psychiatry Investig        ISSN: 1738-3684            Impact factor:   2.505


  28 in total

1.  A new potential of blood oxygenation level dependent (BOLD) functional MRI for evaluating cerebral centers of penile erection.

Authors:  K Park; J J Seo; H K Kang; S B Ryu; H J Kim; G W Jeong
Journal:  Int J Impot Res       Date:  2001-04       Impact factor: 2.896

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

4.  Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype.

Authors:  G McAllister; A Charlesworth; C Snodin; M S Beer; A J Noble; D N Middlemiss; L L Iversen; P Whiting
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

5.  Patterns of brain activation during visually evoked sexual arousal differ between homosexual and heterosexual men.

Authors:  S-H Hu; N Wei; Q-D Wang; L-Q Yan; E-Q Wei; M-M Zhang; J-B Hu; M-L Huang; W-H Zhou; Y Xu
Journal:  AJNR Am J Neuroradiol       Date:  2008-09-03       Impact factor: 3.825

6.  Two sexually dimorphic cell groups in the human brain.

Authors:  L S Allen; M Hines; J E Shryne; R A Gorski
Journal:  J Neurosci       Date:  1989-02       Impact factor: 6.167

7.  Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors.

Authors:  Nahit Kamil Ozmenler; Tunay Karlidere; Ali Bozkurt; Sinan Yetkin; Ali Doruk; Levent Sutcigil; Adnan Cansever; Ozcan Uzun; Fuat Ozgen; Aytekin Ozsahin
Journal:  Hum Psychopharmacol       Date:  2008-06       Impact factor: 1.672

8.  Assessment of sexual function, interest and activity in depressed men.

Authors:  J R Howell; C F Reynolds; M E Thase; E Frank; J R Jennings; P R Houck; S Berman; E Jacobs; D J Kupfer
Journal:  J Affect Disord       Date:  1987 Jul-Aug       Impact factor: 4.839

9.  Assessment of cerebrocortical areas associated with sexual arousal in depressive women using functional MR imaging.

Authors:  Jong-Chul Yang; Kwangsung Park; Sung-Jong Eun; Moo-Suk Lee; Jin-Sang Yoon; Il-Seon Shin; Yong-Ku Kim; Tae-Woong Chung; Heoung-Keun Kang; Gwang-Woo Jeong
Journal:  J Sex Med       Date:  2008-01-10       Impact factor: 3.802

10.  Treatment with selective serotonin reuptake inhibitors and mirtapazine results in differential brain activation by visual erotic stimuli in patients with major depressive disorder.

Authors:  Won Kim; Bo-Ra Jin; Wan-Seok Yang; Kyuong-Uk Lee; Ra-Hyung Juh; Kook-Jin Ahn; Yong-An Chung; Jeong-Ho Chae
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more
  4 in total

1.  Relationship between SSRI-induced sexual dysfunction and central serotonergic activity based on the loudness dependence of auditory evoked potentials.

Authors:  Young-Min Park
Journal:  Psychopharmacology (Berl)       Date:  2013-09-05       Impact factor: 4.530

Review 2.  Anatomical Markers of Activity in Hypothalamic Neurons.

Authors:  Gloria E Hoffman
Journal:  Compr Physiol       Date:  2020-03-12       Impact factor: 8.915

3.  Neural correlates of emotion processing comparing antidepressants and exogenous oxytocin in postpartum depressed women: An exploratory study.

Authors:  Tierney K Lorenz; Hu Cheng; Julia R Heiman
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 4.  Amitriptyline and Sexual Function: A Systematic Review Updated for Sexual Health Practice.

Authors:  Louis Wei-Hsi Chen; Melody Yun-Si Chen; Zhi-Ping Lian; Hung-Sheng Lin; Chia-Chang Chien; Hsin-Ling Yin; Yuan-Hsiang Chu; Kuo-Yen Chen
Journal:  Am J Mens Health       Date:  2017-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.